{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T10:18:58Z","timestamp":1772619538675,"version":"3.50.1"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003995","name":"Anhui Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["2024AH050693"],"award-info":[{"award-number":["2024AH050693"]}],"id":[{"id":"10.13039\/501100003995","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Computers in Biology and Medicine"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.compbiomed.2025.109964","type":"journal-article","created":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T08:45:16Z","timestamp":1741077916000},"page":"109964","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Discovery of mutations predictive of survival benefit from immunotherapy in first-line NSCLC: A retrospective machine learning study of IMpower150 liquid biopsy data"],"prefix":"10.1016","volume":"189","author":[{"given":"Min","family":"Yuan","sequence":"first","affiliation":[]},{"given":"Wei","family":"Feng","sequence":"additional","affiliation":[]},{"given":"Haolun","family":"Ding","sequence":"additional","affiliation":[]},{"given":"Yaning","family":"Yang","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6997-5533","authenticated-orcid":false,"given":"Xu Steven","family":"Xu","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.compbiomed.2025.109964_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"8","key":"10.1016\/j.compbiomed.2025.109964_bib2","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.mayocp.2019.01.013","article-title":"Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment","volume":"94","author":"Duma","year":"2019","journal-title":"Mayo Clin. Proc."},{"issue":"3","key":"10.1016\/j.compbiomed.2025.109964_bib3","doi-asserted-by":"crossref","first-page":"181","DOI":"10.4132\/jptm.2021.03.23","article-title":"Molecular biomarker testing for non-small cell lung cancer: consensus statement of the Korean Cardiopulmonary Pathology Study Group","volume":"55","author":"Chang","year":"2021","journal-title":"J. Pathol. Transl. Med."},{"issue":"10","key":"10.1016\/j.compbiomed.2025.109964_bib4","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1007\/s12325-019-01057-7","article-title":"Programmed death ligand 1 (PD-L1) as a predictive biomarker for pembrolizumab therapy in patients with advanced non-small-cell lung cancer (NSCLC)","volume":"36","author":"Incorvaia","year":"2019","journal-title":"Adv. Ther."},{"issue":"10","key":"10.1016\/j.compbiomed.2025.109964_bib5","doi-asserted-by":"crossref","first-page":"S126","DOI":"10.1016\/j.jtho.2019.08.265","article-title":"JCSE01.05 biomarker in immunotherapy: myth or reality?","volume":"14","author":"Addeo","year":"2019","journal-title":"J. Thorac. Oncol."},{"issue":"6","key":"10.1016\/j.compbiomed.2025.109964_bib6","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41571-019-0173-9","article-title":"Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC","volume":"16","author":"Camidge","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.compbiomed.2025.109964_bib7","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1158\/2159-8290.CD-20-0522","article-title":"Tumor mutational burden as a predictive biomarker in solid tumors","volume":"10","author":"Sha","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.compbiomed.2025.109964_bib8","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1200\/EDBK_280795","article-title":"Checkpoint blockade in lung cancer with driver mutation: choose the road wisely","volume":"40","author":"Calles","year":"2020","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"10.1016\/j.compbiomed.2025.109964_bib9","article-title":"Future perspective for the application of predictive biomarker testing in advanced stage non-small cell lung cancer","volume":"38","author":"de Jager","year":"2024","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.compbiomed.2025.109964_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.750657","article-title":"Immunotherapy in non-small cell lung cancer with actionable mutations other than EGFR","volume":"11","author":"Seegobin","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.compbiomed.2025.109964_bib11","article-title":"Clinical and genomic features of response and toxicity to sotorasib in a real-world cohort of patients with advanced KRAS G12C-mutant non-small cell lung cancer","volume":"7","author":"Thummalapalli","year":"2023","journal-title":"JCO Precis Oncol."},{"issue":"4","key":"10.1016\/j.compbiomed.2025.109964_bib12","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.annonc.2023.01.011","article-title":"Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC","volume":"34","author":"Mok","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.compbiomed.2025.109964_bib13","article-title":"Association of PTPRD\/PTPRT mutation with better clinical outcomes in NSCLC patients treated with immune checkpoint blockades","volume":"11","author":"Wang","year":"2021","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.compbiomed.2025.109964_bib14","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1186\/s12916-021-02075-5","article-title":"Identification and validation of tissue or ctDNA PTPRD phosphatase domain deleterious mutations as prognostic and predictive biomarkers for immune checkpoint inhibitors in non-squamous NSCLC","volume":"19","author":"Sun","year":"2021","journal-title":"BMC Med."},{"issue":"1","key":"10.1016\/j.compbiomed.2025.109964_bib15","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41698-021-00243-7","article-title":"Co-occurring genomic alterations and immunotherapy efficacy in NSCLC","volume":"6","author":"Zhang","year":"2022","journal-title":"npj Precis. Oncol."},{"issue":"2","key":"10.1016\/j.compbiomed.2025.109964_bib16","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1158\/1078-0432.CCR-17-1841","article-title":"Effects of Co-occurring genomic alterations on outcomes in patients with KRAS-mutant non-small cell lung cancer","volume":"24","author":"Arbour","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.compbiomed.2025.109964_bib17","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003027","article-title":"Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial","volume":"10","author":"West","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"4","key":"10.1016\/j.compbiomed.2025.109964_bib18","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1038\/s41591-023-02226-6","article-title":"A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer","volume":"29","author":"Assaf","year":"2023","journal-title":"Nat. Med."},{"issue":"21","key":"10.1016\/j.compbiomed.2025.109964_bib19","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non\u2013small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"26","key":"10.1016\/j.compbiomed.2025.109964_bib20","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"16","key":"10.1016\/j.compbiomed.2025.109964_bib21","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.compbiomed.2025.109964_bib22","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non\u2013small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"10064","key":"10.1016\/j.compbiomed.2025.109964_bib23","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.compbiomed.2025.109964_bib24","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2018.0013","article-title":"Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial","volume":"4","author":"Fuchs","year":"2018","journal-title":"JAMA Oncol."},{"issue":"17","key":"10.1016\/j.compbiomed.2025.109964_bib25","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.18.01265","article-title":"Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study","volume":"37","author":"Chung","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.compbiomed.2025.109964_bib26","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1172\/JCI91190","article-title":"IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J. Clin. Investig."},{"issue":"1","key":"10.1016\/j.compbiomed.2025.109964_bib27","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41698-024-00651-5","article-title":"Multi-omics analysis unveils immunosuppressive microenvironment in the occurrence and development of multiple pulmonary lung cancers","volume":"8","author":"Zhang","year":"2024","journal-title":"npj Precis. Oncol."},{"issue":"6","key":"10.1016\/j.compbiomed.2025.109964_bib28","doi-asserted-by":"crossref","first-page":"5361","DOI":"10.3934\/mbe.2022251","article-title":"An integrative prognostic and immune analysis of PTPRD in cancer","volume":"19","author":"Ou","year":"2022","journal-title":"Math. Biosci. Eng."},{"key":"10.1016\/j.compbiomed.2025.109964_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.991091","article-title":"PTPRD\/PTPRT mutation as a predictive biomarker of immune checkpoint inhibitors across multiple cancer types","volume":"13","author":"Shang","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.compbiomed.2025.109964_bib30","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1146\/annurev-immunol-110416-120628","article-title":"Disorders of the JAK\/STAT pathway in T cell lymphoma pathogenesis: implications for immunotherapy","volume":"35","author":"Waldmann","year":"2017","journal-title":"Annu. Rev. Immunol."},{"issue":"11","key":"10.1016\/j.compbiomed.2025.109964_bib31","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1093\/carcin\/bgaa059","article-title":"Modulation of the PD-1\/PD-L1 immune checkpoint axis during inflammation-associated lung tumorigenesis","volume":"41","author":"Narayanapillai","year":"2020","journal-title":"Carcinogenesis"},{"issue":"3\u20134","key":"10.1016\/j.compbiomed.2025.109964_bib32","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1080\/08830180902978120","article-title":"Molecular mechanisms of IFN-gamma to up-regulate MHC class I antigen processing and presentation","volume":"28","author":"Zhou","year":"2009","journal-title":"Int. Rev. Immunol."},{"issue":"16","key":"10.1016\/j.compbiomed.2025.109964_bib33","doi-asserted-by":"crossref","first-page":"8204","DOI":"10.18632\/aging.204964","article-title":"PTPRD mutation is a prognostic biomarker for sensitivity to ICIs treatment in advanced non-small cell lung cancer","volume":"15","author":"Ren","year":"2023","journal-title":"Aging (Albany NY)"},{"issue":"1","key":"10.1016\/j.compbiomed.2025.109964_bib34","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-15714-5","article-title":"Patients deriving long-term benefit from immune checkpoint inhibitors demonstrate conserved patterns of site-specific mutations","volume":"12","author":"Principe","year":"2022","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.compbiomed.2025.109964_bib35","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1002\/cam4.4472","article-title":"Association of PTPRT mutations with immune checkpoint inhibitors response and outcome in melanoma and non-small cell lung cancer","volume":"11","author":"Zhang","year":"2022","journal-title":"Cancer Med."},{"issue":"6","key":"10.1016\/j.compbiomed.2025.109964_bib36","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1093\/oncolo\/oyac040","article-title":"Immune-Desert tumor microenvironment in thoracic SMARCA4-deficient undifferentiated tumors with limited efficacy of immune checkpoint inhibitors","volume":"27","author":"Gantzer","year":"2022","journal-title":"Oncologist"},{"issue":"12","key":"10.1016\/j.compbiomed.2025.109964_bib37","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1002\/2211-5463.13899","article-title":"SMARCA4 mutations and expression in lung adenocarcinoma: prognostic significance and impact on the immunotherapy response","volume":"14","author":"Zhang","year":"2024","journal-title":"FEBS Open Bio"},{"issue":"21","key":"10.1016\/j.compbiomed.2025.109964_bib38","doi-asserted-by":"crossref","first-page":"5701","DOI":"10.1158\/1078-0432.CCR-20-1825","article-title":"The genomic landscape of SMARCA4 alterations and associations with outcomes in patients with lung cancer","volume":"26","author":"Schoenfeld","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.compbiomed.2025.109964_bib39","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.cllc.2022.03.005","article-title":"Efficacy of immune checkpoint inhibitors in SMARCA4-deficient thoracic tumor","volume":"23","author":"Shinno","year":"2022","journal-title":"Clin. Lung Cancer"},{"issue":"8","key":"10.1016\/j.compbiomed.2025.109964_bib40","doi-asserted-by":"crossref","first-page":"e133","DOI":"10.1016\/j.jtho.2020.03.030","article-title":"Efficacy of immune checkpoint inhibitors in SMARCA4-mutant NSCLC","volume":"15","author":"Zhou","year":"2020","journal-title":"J. Thorac. Oncol."},{"issue":"12","key":"10.1016\/j.compbiomed.2025.109964_bib41","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1158\/1535-7163.MCT-21-0433","article-title":"SMARCA4: implications of an altered chromatin-remodeling gene for cancer development and therapy","volume":"20","author":"Mardinian","year":"2021","journal-title":"Mol. Cancer Therapeut."},{"issue":"2","key":"10.1016\/j.compbiomed.2025.109964_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.ygeno.2024.110808","article-title":"Clinical value of FAT1 mutations to indicate the immune response in colorectal cancer patients","volume":"116","author":"Zhu","year":"2024","journal-title":"Genomics"},{"issue":"1","key":"10.1016\/j.compbiomed.2025.109964_bib43","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s41698-022-00292-6","article-title":"Favorable immune checkpoint inhibitor outcome of patients with melanoma and NSCLC harboring FAT1 mutations","volume":"6","author":"Zhang","year":"2022","journal-title":"npj Precis. Oncol."},{"issue":"8","key":"10.1016\/j.compbiomed.2025.109964_bib44","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.annonc.2022.05.520","article-title":"ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group","volume":"33","author":"Pascual","year":"2022","journal-title":"Ann. Oncol."}],"container-title":["Computers in Biology and Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010482525003154?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010482525003154?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T17:22:51Z","timestamp":1769275371000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0010482525003154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":44,"alternative-id":["S0010482525003154"],"URL":"https:\/\/doi.org\/10.1016\/j.compbiomed.2025.109964","relation":{},"ISSN":["0010-4825"],"issn-type":[{"value":"0010-4825","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of mutations predictive of survival benefit from immunotherapy in first-line NSCLC: A retrospective machine learning study of IMpower150 liquid biopsy data","name":"articletitle","label":"Article Title"},{"value":"Computers in Biology and Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.compbiomed.2025.109964","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109964"}}